# Prof. Vehbi Alp ÜÇOK

## Personal Information

**Email:** alpucok@istanbul.edu.tr
**Web:** http://aves.istanbul.edu.tr/1508/

**International Researcher IDs**
ORCID: 0000-0002-8985-5747
Publons / Web Of Science ResearcherID: AAD-1539-2019
Yoksis Researcher ID: 10699

## Education Information

Expertise In Medicine, Istanbul University, Istanbul Medical Faculty, Psikiyatri Anabilim Dalı, Turkey 1988 - 1993
Undergraduate, Hacettepe University, Tıp Fakültesi, Turkey 1979 - 1985

## Foreign Languages

English, B2 Upper Intermediate

## Dissertations

Expertise In Medicine, İkiuçlu duygudurum bozukluğunun koruyucu tedavisinde lityuma yanıtın prediktörleri, Istanbul University, Istanbul Medical Faculty, Psikiyatri Anabilim Dalı, 1993

## Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Psychiatry

## Academic Titles / Tasks

Professor, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , 2001 - Continues

## Published journal articles indexed by SCI, SSCI, and AHCI

I. **Discriminant analysis using MRI asymmetry indices and cognitive scores of women with temporal lobe epilepsy or schizophrenia**
Fırat Z., Er F., Noyan H., Ekinci G., Üçok A., Uluğ A. M., Aktekin B.
Neuroradiology, 2024 (SCI-Expanded)

II. **Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation.**
van der Meer D., Cheng W., Rokicki J., Fernandez-Cabello S., Shadrin A., Smeland O. B., Ehrhart F., Gülöksüz S., Pries L., Lin B., et al.

Schizophrenia bulletin, 2023 (SCI-Expanded)

III. **Minor physical anomalies may be related to treatment resistance in patients with schizophrenia.**
Uğurpala C., Berberoğlu E., Özkan U., Genç S. A., Tanrıverdi N. Ç., İnhanlı D., Ali C., Üçok A.
Asian journal of psychiatry, vol.88, pp.103729, 2023 (SCI-Expanded)

IV. **Measuring discrimination experienced by people with a mental illness: replication of the short-form DISCUS in six world regions**
Brohan E., Thornicroft G., Rusch N., Lasalvia A., Campbell M. M., YALÇINKAYA ALKAR Ö., Lanfredi M., Ochoa S., Ucok A., Tomas C., et al.
PSYCHOLOGICAL MEDICINE, vol.53, no.9, pp.3963-3973, 2023 (SCI-Expanded)

V. **Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study.**
Fusar-Poli L., Prachason T., Erzin G., Pries L., Brondino N., Politi P., Delespaul P., Kenis G., Luykx J. J., Lin B. D., et al.
Psychiatry research, vol.323, pp.115184, 2023 (SCI-Expanded)

VI. **Visual P3 abnormalities in patients with first-episode schizophrenia, unaffected siblings of schizophrenia patients and individuals at ultra-high risk for psychosis.**
Devrim-Üçok M., Keskin-Ergen H. Y., Üçok A.
Progress in neuro-psychopharmacology & biological psychiatry, vol.122, pp.110678, 2023 (SCI-Expanded)

VII. **Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium.**
Smart S. E., Agbedjro D., Pardiñas A. F., Ajnakina O., Alameda L., Andreassen O. A., Barnes T. R., Berardi D., Camporesi S., Cleusix M., et al.
Schizophrenia research, vol.250, pp.1-9, 2022 (SCI-Expanded)

VIII. **The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study**
Fusar-Poli L., Pries L., van Os J., Radhakrishnan R., Pence A. Y., Erzin G., Delespaul P., Kenis G., Luykx J. J., Lin B. D., et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol.63, pp.1-14, 2022 (SCI-Expanded)

IX. **Impaired Effort Allocation in Patients with Recent-Onset Schizophrenia and Its Relevance to Negative Symptoms Assessments and Persistent Negative Symptoms**
Ince Guliyev E., Guloksuz S., Ucok A.
JOURNAL OF CLINICAL MEDICINE, vol.11, no.17, 2022 (SCI-Expanded)

X. **Validation of the Turkish version of the self-evaluation of negative symptoms scale (SNS).**
Polat I., Ince Guliyev E., Elmas S., Karakaş S., Aydemir Ö., Üçok A.
International journal of psychiatry in clinical practice, vol.26, no.3, pp.221-227, 2022 (SCI-Expanded)

XI. **Menstrual Cycle-Related Changes in Women with Schizophrenia: A Resting-State fMRI Study**
Noyan H., HAMAMCI A., Firat Z., Sarsilmaz A., Ucok A.
NEUROPSYCHOBIOLOGY, vol.81, no.4, pp.296-310, 2022 (SCI-Expanded)

XII. **Mapping genomic loci implicates genes and synaptic biology in schizophrenia.**
Trubetskoy V., Pardiñas A. F., Qi T., Panagiotaropoulou G., Awasthi S., Bigdeli T. B., Bryois J., Chen C., Dennison C. A., Hall L. S., et al.
Nature, vol.604, no.7906, pp.502-508, 2022 (SCI-Expanded)

XIII. **Altered Resting State Functional Connectivity and Its Correlation with Cognitive Functions at Ultra High Risk for Psychosis**
Bulbul O., Kurt E., Ulasoglu-Yildiz Ç., Demiralp T., Ucok A.
PSYCHIATRY RESEARCH-NEUROIMAGING, vol.321, 2022 (SCI-Expanded)

XIV. **Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study**
Fusar-Poli L., Pries L., van Os J., Erzin G., Delespaul P., Kenis G., Luykx J. J., Lin B. D., Richards A. L., Akdede B., et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.113, 2022 (SCI-Expanded)

XV. **European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study**

Dollfus S., Mucci A., Giordano G. M., Bitter I., Austin S. F., Delouche C., Erfurth A., Fleischhacker W. W., Movina L., Glenthoj B., et al.
FRONTIERS IN PSYCHIATRY, vol.13, 2022 (SCI-Expanded)

XVI. **Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings**
Noyan H., ERDAĞ E., TÜZÜN E., YAYLIM İ., KÜÇÜKHÜSEYİN Ö., HAKAN M. T., Gülöksüz S., Rutten B. P., SAKA M. C., Atbaşoğlu C., et al.
Schizophrenia Research, vol.229, pp.27-37, 2021 (SCI-Expanded)

XVII. **Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum**
Pries L. -., Dal Ferro G. A., van Os J., Delespaul P., Kenis G., Lin B. D., Luykx J. J., Richards A. L., Akdede B., Binbay T., et al.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, vol.29, 2020 (SCI-Expanded)

XVIII. **Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia A Real-World Multicenter, Retrospective, Mirror-Image Study**
Devrimci-Ozguven H., ATMACA M., Baran Z., Cengisiz C., Cinar C., Erol A., Genc Y., Karadag H., Karakulah K., Karasu U., et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol.39, no.6, pp.604-610, 2019 (SCI-Expanded)

XIX. **White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?**
Schepers E., Lousberg R., Guloksuz S., Pries L., Delespaul P., Kenis G., Luykx J. J., Lin B. D., Richards A. L., Akdede B., et al.
FRONTIERS IN PSYCHIATRY, vol.10, 2019 (SCI-Expanded)

XX. **Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study**
Pries L., Lage-Castellanos A., Delespaul P., Kenis G., Luykx J. J., Lin B. D., Richards A. L., Akdede B., Binbay T., ALTINYAZAR V., et al.
SCHIZOPHRENIA BULLETIN, vol.45, no.5, pp.960-965, 2019 (SCI-Expanded)

XXI. **A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale**
Mucci A., Vignapiano A., Bitter I., Austin S. F., Delouche C., Dollfus S., Erfurth A., Fleischhacker W. W., Giordano G. M., Gladyshev I., et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol.29, no.8, pp.947-959, 2019 (SCI-Expanded)

XXII. **Lower prepulse inhibition in clinical high-risk groups but not in familial risk groups for psychosis compared with healthy controls**
Togay B., Cikrikcili U., Bayraktaroglu Z., Uslu A., Noyan H., Ucok A.
EARLY INTERVENTION IN PSYCHIATRY, 2019 (SCI-Expanded)

XXIII. **Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study**
Guloksuz S., Pries L., Delespaul P., Kenis G., Luykx J. J., Lin B. D., Richards A. L., Akdede B., Binbay T., ALTINYAZAR V., et al.
WORLD PSYCHIATRY, vol.18, no.2, pp.173-182, 2019 (SCI-Expanded)

XXIV. **Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia**
Ucok A., Yagcioglu E. A., YILDIZ M., Kaymak S. U., SAKA M. C., Tasdelen R., DANACI A. E., Senol S. H.
PSYCHIATRY RESEARCH, vol.275, pp.149-154, 2019 (SCI-Expanded)

XXV. **Psychometric liability to psychosis and childhood adversities are associated with shorter telomere length: A study on schizophrenia patients, unaffected siblings, and non-clinical controls**
Cevik B., MANÇE ÇALIŞIR Ö., Atbasoglu E. C., SAKA M. C., ALPTEKİN K., ÜÇOK V. A., Sirmatel B., Guloksuz S., Tukun A., van Os J., et al.
JOURNAL OF PSYCHIATRIC RESEARCH, vol.111, pp.169-185, 2019 (SCI-Expanded)

XXVI. **Responding to experienced and anticipated discrimination (READ): anti -stigma training for medical students towards patients with mental illness - study protocol for an international multisite non-randomised controlled study**

Deb T., Lempp H., Bakolis I., Vince T., Waugh W., Henderson C., Thornicroft G., Ando S., Yamaguchi S., Matsunaga A., et al.
BMC MEDICAL EDUCATION, vol.19, 2019 (SCI-Expanded)

XXVII. **The impact of a six-month interpersonal group psychotherapy on functionality of patients with schizophrenia in a community mental health center**
Sukru F., Ozturk M., Kilic O., Ister Guneytepe S., Ucok A.
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.19, no.6, pp.559-566, 2018 (SCI-Expanded)

XXVIII. **Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia**
ATBAŞOĞLU E. C., Gumus-Akay G., Guloksuz S., SAKA M. C., Ucok A., ALPTEKİN K., GÜLLÜ S., van Os J.
PSYCHOPHARMACOLOGY, vol.235, no.4, pp.1029-1039, 2018 (SCI-Expanded)

XXIX. **Relationship of obsessive-compulsive symptoms to clinical variables and cognitive functions in individuals at ultra high risk for psychosis**
Soyata A. Z., Akisik S., Inhanli D., Noyan H., Ucok A.
PSYCHIATRY RESEARCH, vol.261, pp.332-337, 2018 (SCI-Expanded)

XXX. **Electrophysiological and Neuroimaging Research on Negative Symptoms: Future Challenges**
Mucci A., Ucok A., Nielsen M. O.
CLINICAL EEG AND NEUROSCIENCE, vol.49, no.1, pp.3-5, 2018 (SCI-Expanded)

XXXI. **Relationship Between Persistent Negative Symptoms and Findings of Neurocognition and Neuroimaging in Schizophrenia**
Ince E., Ucok A.
CLINICAL EEG AND NEUROSCIENCE, no.1, pp.27-35, 2018 (SCI-Expanded)

XXXII. **Deficits in Go and NoGo P3 potentials in patients with schizophrenia.**
ERTEKIN E., Üçok A., KESKIN-ERGEN Y., DEVRIM-ÜÇOK M.
Psychiatry research, vol.254, pp.126-132, 2017 (SCI-Expanded)

XXXIII. **Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases**
Mucci A., MERLOTTI E., Ucok A., ALEMAN A., Galderisi S.
SCHIZOPHRENIA RESEARCH, vol.186, pp.19-28, 2017 (SCI-Expanded)

XXXIV. **Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology**
Howes O. D., McCutcheon R., Agid O., de Bartolomeis A., van Beveren N. J. M., Birnbaum M. L., Bloomfield M. A. P., Bressan R. A., Buchanan R. W., Carpenter W. T., et al.
AMERICAN JOURNAL OF PSYCHIATRY, vol.174, no.3, pp.216-229, 2017 (SCI-Expanded)

XXXV. **The Relationship of Negative Symptom Severity with Cognitive Symptoms and Functioning in Subjects at Ultra High Risk for Psychosis**
Ucok A., Cikrikcili U., Noyan H., Tabak O., Yokusoglu C., Samanli H. K., Ergul C., Caglar N.
EARLY INTERVENTION IN PSYCHIATRY, vol.10, pp.88, 2016 (SCI-Expanded)

XXXVI. **Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study**
Ucok A., Cikrikcili U., Ergul C., Tabak O., Salaj A., Karabulut S., CORRELL C. U.
CNS DRUGS, vol.30, no.10, pp.997-1006, 2016 (SCI-Expanded)

XXXVII. **Lack of progressive reduction in P3 amplitude after the first-episode of schizophrenia: A 6-year follow-up study**
Devrim-Ucok M., Keskin-Ergen Y., Ucok A.
PSYCHIATRY RESEARCH, vol.243, pp.303-311, 2016 (SCI-Expanded)

XXXVIII. **Validation of Turkish version of brief negative symptom scale**
Polat Nazli I., Ergul C., Aydemir O., Chandhoke S., Ucok A., Gönül A. S.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, vol.20, no.4, pp.265-271, 2016 (SCI-Expanded)

XXXIX. **Discrimination in the workplace, reported by people with major depressive disorder: a cross-**

**sectional study in 35 countries**
Brouwers E. P. M., Mathijssen J., Van Bortel T., Knifton L., Wahlbeck K., Van Audenhove C., Kadri N., Chang C., Goud B. R., Ballester D., et al.
BMJ OPEN, vol.6, no.2, 2016 (SCI-Expanded)

XL. **Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia**
Schreiner A., Aadamsoo K., Altamura A. C., Franco M., Gorwood P., Neznanov N. G., SCHRONEN J., Ucok A., ZINK M., JANIK A., et al.
SCHIZOPHRENIA RESEARCH, vol.169, pp.393-399, 2015 (SCI-Expanded)

XLI. **Clinical variables associated with suicide attempts in schizophrenia before and after the first episode**
Togay B., Noyan H., Tasdelen R., Ucok A.
PSYCHIATRY RESEARCH, vol.229, pp.252-256, 2015 (SCI-Expanded)

XLII. **Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia**
Ucok A., Cikrikcili U., Karabulut S., Salaj A., Ozturk M., Tabak O., Durak R.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, vol.30, no.5, pp.290-295, 2015 (SCI-Expanded)

XLIII. **Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study**
Ucok A., Saka M. C., BILICI M.
NORDIC JOURNAL OF PSYCHIATRY, vol.69, no.6, pp.1708-1714, 2015 (SCI-Expanded)

XLIV. **Negative symptom subgroups have different effects on the clinical course of schizophrenia after the first episode: A 24-month follow up study**
Ergul C., Ucok A.
EUROPEAN PSYCHIATRY, vol.30, no.1, 2015 (SCI-Expanded)

XLV. **Obsessive compulsive symptoms are related to lower quality of life in patients with Schizophrenia**
Ucok A., Tihan A. K., Karadayi G., Tukel R.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, vol.18, no.4, pp.243-247, 2014 (SCI-Expanded)

XLVI. **Treatment Guidelines for Patients with Schizophrenia or Psychotic Disorder who are Hospitalized in a Psychiatry Clinic**
ALPTEKİN K., Ucok A., Ayer A., Unal A., Erol A., Ensari H., ATMACA M., ÖZGÜVEN H.
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.24, no.3, pp.276-288, 2014 (SCI-Expanded)

XLVII. **Persistent negative symptoms after first episode schizophrenia: A 2-year follow-up study**
Ucok A., Ergul C.
SCHIZOPHRENIA RESEARCH, vol.158, pp.241-246, 2014 (SCI-Expanded)

XLVIII. **Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations**
van Os J., Rutten B. P., Myin-Germeys I., Delespaul P., Viechtbauer W., van Zelst C., Bruggeman R., Reininghaus U., Morgan C., Murray R. M., et al.
SCHIZOPHRENIA BULLETIN, vol.40, no.4, pp.729-736, 2014 (SCI-Expanded)

XLIX. **The role of metformin and topiramate in reducing the side effects due to antipsychotics in patients with schizophrenia**
Karabulut S., Ergul C., Ozturk M., Ucok A.
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.15, no.2, pp.174-180, 2014 (SCI-Expanded)

L. **Factor structure of the Subjective Well-being under Neuroleptic treatment Scale-short form in schizophrenic outpatients: Five factors or only one?**
Pazvantoglu O., Simsek O. F., Aydemir O., Sarisoy G., Boke O., Ucok A.
NORDIC JOURNAL OF PSYCHIATRY, vol.68, no.4, pp.259-265, 2014 (SCI-Expanded)

LI. **P3 ABNORMALITIES IN NEUROLEPTIC-NAIVE FIRST-EPISODE SCHIZOPHRENIA PATIENTS AND IN THEIR HEALTHY SIBLINGS**

Devrim-Ucok M., Ucok A.
SCHIZOPHRENIA RESEARCH, vol.153, 2014 (SCI-Expanded)

LII. **PERSISTANT NEGATIVE SYMPTOMS AFTER FIRST-EPISODE SCHIZOPHRENIA; RESULTS OF 2 YEARS FOLLOW-UP**
Ucok A., Ergul C.
SCHIZOPHRENIA RESEARCH, vol.153, 2014 (SCI-Expanded)

LIII. **NEGATIVE SYMPTOM SUBGROUPS HAVE DIFFERENT EFFECTS ON CLINICAL COURSE AFTER FIRST EPISODE OF SCHIZOPHRENIA: A 24 MONTHS FOLLOW-UP STUDY**
Ergul C., Ucok A.
SCHIZOPHRENIA RESEARCH, vol.153, 2014 (SCI-Expanded)

LIV. **NEGATIVE SYMPTOM SUBGROUPS HAVE DIFFERENT EFFECTS ON CLINICAL COURSE AFTER FIRST EPISODE OF SCHIZOPHRENIA: A 24-MONTH FOLLOW-UP STUDY**
Ergul C., Ucok A.
SCHIZOPHRENIA RESEARCH, vol.153, 2014 (SCI-Expanded)

LV. **A RANDOMIZED, ACTIVE-CONTROLLED RATER-BLINDED 2-YEAR STUDY OF PALIPERIDONE PALMITATE VERSUS INVESTIGATORS' CHOICE OF ORAL ANTIPSYCHOTIC MONOTHERAPY IN PATIENTS WITH SCHIZOPHRENIA (PROSIPAL)**
Schreiner A., Aadamsoo K., Altamura C., Franco M., Gorwood P., Neznanov N. G., Schronen J., Ucok A., Zink M., Lahaye M., et al.
SCHIZOPHRENIA RESEARCH, vol.153, 2014 (SCI-Expanded)

LVI. **A RANDOMIZED, ACTIVE-CONTROLLED RATER-BLINDED 2-YEAR STUDY OF PALIPERIDONE PALMITATE VERSUS INVESTIGATORS' CHOICE OF ORAL ANTIPSYCHOTIC MONOTHERAPY IN PATIENTS WITH SCHIZOPHRENIA (PROSIPAL)**
Schreiner A., Aadamsoo K., Altamura A. C., Franco M., Goorwood P., Neznanov N. G., Schronen J., Ucok A., Zink M., Cherubin P., et al.
EUROPEAN PSYCHIATRY, vol.29, 2014 (SCI-Expanded)

LVII. **Cognitive deficits in clinical and familial high risk groups for psychosis are common as in first episode schizophrenia**
Ucok A., Direk N., KOYUNCU A., Keskin-Ergen Y., Yuksel C., GULER J., Karadayi G., Akturan E., Devrim-Ucok M.
SCHIZOPHRENIA RESEARCH, vol.151, pp.265-269, 2013 (SCI-Expanded)

LVIII. **The history of childhood trauma among individuals with ultra high risk for psychosis is as common as among patients with first-episode schizophrenia**
Sahin S., Yuksel C., GULER J., Karadayi G., Akturan E., Gode E., Ozhan A. A., Ucok A.
EARLY INTERVENTION IN PSYCHIATRY, vol.7, no.4, pp.414-420, 2013 (SCI-Expanded)

LIX. **Anticipated discrimination is related to symptom severity, functionality and quality of life in schizophrenia**
Ucok A., Karadayi G., Emiroglu B., sartorius N.
PSYCHIATRY RESEARCH, vol.209, no.3, pp.333-339, 2013 (SCI-Expanded)

LX. **Reliability and Validity of Subjective Well-Being Under Neuroleptics Scale-Short Form-Turkish Version**
Pazvantoglu O., Simsek O. F., AYDEMİR Ö., SARISOY G., Korkmaz I. Z., Mor S., BÖKE Ö., Ucok A.
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.22, no.3, pp.235-243, 2012 (SCI-Expanded)

LXI. **Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With Schizophrenia A Prospective, Randomized, Controlled Trial**
Schreiner A., Niehaus D., Shuriquie N. A., Aadamsoo K., Korcsog P., Salinas R., Theodoropoulou P., Garcia Fernandez L., Ucok A., Tessier C., et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol.32, no.4, pp.449-457, 2012 (SCI-Expanded)

LXII. **No gender differences in social outcome in patients suffering from schizophrenia**
Galderisi s., bucci p., Ucok A., Peuskens J.
EUROPEAN PSYCHIATRY, vol.27, no.6, pp.406-408, 2012 (SCI-Expanded)

LXIII. **Employment and its relationship with functionality and quality of life in patients with schizophrenia: EGOFORS Study**
Ucok A., Gorwood P., Karadayi G.
EUROPEAN PSYCHIATRY, vol.27, no.6, pp.422-425, 2012 (SCI-Expanded)

LXIV. **OBSESSIVE COMPULSIVE SYMPTOMS BUT NOT OBSESSIVE-COMPULSIVE DISORDER ARE RELATED TO LOWER QUALITY OF LIFE IN SCHIZOPHRENIA**
ÜÇOK V. A., Tihan A., Tukel R.
SCHIZOPHRENIA RESEARCH, vol.136, 2012 (SCI-Expanded)

LXV. **Self-stigmatization among patients with schizophrenia, their relatives and patients with major depressive disorder**
YILDIZ M., Ozten E., Isik S., Ozyildirim I., Karayun D., Cerit C., Ucok A.
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.13, no.1, pp.1-7, 2012 (SCI-Expanded)

LXVI. **Anticipated discrimination among people with schizophrenia**
Ucok A., Brohan E., Rose D., Sartorius N., Leese M., Yoon C. K., Plooy A., Ertekin B. A., Milev R., Thornicroft G.
ACTA PSYCHIATRICA SCANDINAVICA, vol.125, no.1, pp.77-83, 2012 (SCI-Expanded)

LXVII. **Bir Üniversite Hastanesi Psikiyatri Servisinde Yatarak Tedavi Edilen Ergen Hastaların Klinik ve Sosyodemografik Özellikleri.**
COŞKUN M., Karakoç S., Ayaydın H., Bozkurt H., SÜLEYMAN F., ZOROĞLU S. S., ÜÇOK V. A.
Çocuk ve Gençlik Ruh Sağlığı Dergisi, vol.19, pp.17-24, 2012 (SCI-Expanded)

LXVIII. **Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia**
Karadayi G., Emiroglu B., Ucok A.
COMPREHENSIVE PSYCHIATRY, vol.52, no.6, pp.701-707, 2011 (SCI-Expanded)

LXIX. **Remission after first-episode schizophrenia: Results of a long-term follow-up**
Ucok A., Serbest S., Kandemir P. E.
PSYCHIATRY RESEARCH, vol.189, no.1, pp.33-37, 2011 (SCI-Expanded)

LXX. **Obsessive compulsive disorder and symptoms may have different effects on schizophrenia**
Ucok A., CEYLAN M. E., Tihan A. K., LAPCIN S., GER C., Tukel R.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.35, no.2, pp.429-433, 2011 (SCI-Expanded)

LXXI. **An Unusual Late Presentation of Subacute Sclerosing Panencephalitis With Psychotic Symptoms**
Baran Z., Hanagasi H. A., Ucok A.
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.22, no.1, 2010 (SCI-Expanded)

LXXII. **COMT Val158Met polymorphism is related with interpersonal problem solving in schizophrenia**
Ucok A., Öztürk M. S., Duman Z., Saruhan-Direskeneli G.
European Psychiatry, vol.25, no.6, pp.320-322, 2010 (SCI-Expanded)

LXXIII. **THE EFFECTIVENESS OF A PSYCHOEDUCATIONAL GROUP PROGRAM WITH INPATIENTS BEING TREATED FOR CHRONIC MENTAL ILLNESS**
DUMAN Z. Ç., Yildirim N. K., Ucok A., Er F., Kanik T.
SOCIAL BEHAVIOR AND PERSONALITY, vol.38, no.5, pp.657-666, 2010 (SSCI)

LXXIV. **Validation of the Turkish Version of the "Functional Remission of General Schizophrenia" (FROGS) Scale**
Emiroglu B., Karadayi G., AYDEMİR Ö., Ucok A.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.46, pp.15-24, 2009 (SCI-Expanded)

LXXV. **Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study**
ALPTEKİN K., Hafez J., Brook S., AKKAYA C., Tzebelikos E., Ucok A., El Tallawy H., DANACI A. E., Lowe W., Karayal O. N.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, vol.24, no.5, pp.229-238, 2009 (SCI-Expanded)

LXXVI. **THE VALIDATION OF TURKISH VERSION OF PERSONAL AND SOCIAL PERFORMANCE SCALE (PSP)**
Aydemir O., Ucok A., Danaci A. E., Sarioz F., Canpolat T., Karadayi G., Emiroglu B.

VALUE IN HEALTH, vol.12, no.3, 2009 (SCI-Expanded)

LXXVII. **Analysis of Social Class by LCA in Patients with Schizophrenia: Change in Psychopathology after 12 Month of Treatment**
Saylan M., Ucok A., Uguz S., Treuer T., Sir A.
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.19, no.1, pp.29-38, 2009 (SCI-Expanded)

LXXVIII. **Altered Metabolic Integrity of Corpus Callosum Among Individuals at Ultra High Risk of Schizophrenia and First-Episode Patients**
Aydin K., Ucok A., GULER J.
BIOLOGICAL PSYCHIATRY, vol.64, no.9, pp.750-757, 2008 (SCI-Expanded)

LXXIX. **Do psychiatrists examine sexual dysfunction in schizophrenia patients?**
Ucok A., Incesu C., Aker T., Erkoc S.
JOURNAL OF SEXUAL MEDICINE, vol.5, no.8, pp.2000-2001, 2008 (SCI-Expanded)

LXXX. **Side effects of atypical antipsychotics: a brief overview**
Ucok A., gaebel W.
WORLD PSYCHIATRY, vol.7, no.1, pp.58-62, 2008 (SCI-Expanded)

LXXXI. **Effectiveness of a structured diet program in antipsychotic-induced weight gain in patients with schizophrenia**
Direk N., Ucok A.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, vol.12, no.3, pp.238-240, 2008 (SCI-Expanded)

LXXXII. **Quantitative proton MR spectroscopy findings in the corpus callosum of patients with schizophrenia suggest callosal disconnection**
Aydin K., Ucok A., Cakir S.
AMERICAN JOURNAL OF NEURORADIOLOGY, vol.28, no.10, pp.1968-1974, 2007 (SCI-Expanded)

LXXXIII. **The effects of childhood trauma in patients with first-episode schizophrenia**
Ucok A., Bikmaz S.
ACTA PSYCHIATRICA SCANDINAVICA, vol.116, no.5, pp.371-377, 2007 (SCI-Expanded)

LXXXIV. **Novelty P3 and P3b in first-episode schizophrenia and chronic schizophrenia**
DEVRIM-UCOK M., KESKIN-ERGEN H. Y., Ucok A.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.30, no.8, pp.1426-1434, 2006 (SCI-Expanded)

LXXXV. **Mismatch negativity at acute and post-acute phases of first-episode schizophrenia**
Derim-Ucok M., Keskin-Ergen H. Y., Ucok A.
INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, vol.61, no.3, pp.345, 2006 (SCI-Expanded)

LXXXVI. **Cognitive predictors of skill acquisition on social problem solving in patients with schizophrenia**
Ucok A., Cakir S., Duman Z. C., Discigal A., Kandemir P., Atli H.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, vol.256, no.6, pp.388-394, 2006 (SCI-Expanded)

LXXXVII. **P300 responses in recent-onset schizophrenia patients elicited during N-back task**
Keskin-Ergen H. Y., Ertekin E., Ucok A., Devrim-Ucok M.
INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, vol.61, no.3, pp.345, 2006 (SCI-Expanded)

LXXXVIII. **Family centered evaluation of treatment outcome in schizophrenia: Marmara family interview for the Assesment of Psychiatric Treatment**
Kuscu M. K., Duman Z. C., Akman M., Ucok A., Goktepe E. O.
TURK PSIKIYATRI DERGISI, vol.17, no.3, pp.192-203, 2006 (SSCI)

LXXXIX. **Effects of an antistigma program on medical students' attitudes towards people with schizophrenia**
Altindag A., Yanik M., Ucok A., Alptekin K., Ozkan M.
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.60, no.3, pp.283-288, 2006 (SCI-Expanded)

XC. **Electroconvulsive therapy in first-episode schizophrenia**
Ucok A., Cakar S.

JOURNAL OF ECT, vol.22, no.1, pp.38-42, 2006 (SCI-Expanded)

XCI. **One year outcome in first episode schizophrenia - Predictors of relapse**
Ucok A., Polat A., Cakir S., Genc A.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, vol.256, no.1, pp.37-43, 2006 (SCI-Expanded)

XCII. **Histories of childhood maltreatment in first-episode schizophrenia**
Ucok A., Bykmaz S.
ACTA PSYCHIATRICA SCANDINAVICA, vol.114, pp.59, 2006 (SCI-Expanded)

XCIII. **Frequency of obsessive compulsive symptoms and disorder in patients with schizophrenia : importence for prognosis**
Ucok A., Tukel R., Ozgen G., Saylan M., Uzuner G.
ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, vol.32, no.1, pp.41-44, 2006 (SCI-Expanded)

XCIV. **Disability in schizophrenia: Clinical correlates and prediction over 1-year follow-up**
Alptekin K., Erkoc S., Gogus A., Kultur S., Mete L., Ucok A., Yazici K.
PSYCHIATRY RESEARCH, vol.135, no.2, pp.103-111, 2005 (SCI-Expanded)

XCV. **Human leukocyte antigen alleles in patients with bipolardisorder in Turkey**
Ucok A., Akar U., Polat A.
EUROPEAN PSYCHIATRY, vol.20, no.1, pp.83, 2005 (SCI-Expanded)

XCVI. **Cigarette smoking among patients with schizophrenia and bipolar disorders**
Ucok A., Polat A., Bozkurt O., Meteris H.
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.58, no.4, pp.434-437, 2004 (SCI-Expanded)

XCVII. **Bipolar disorder treatment guidelines of Psychiatric Association of Turkey: Main differences as reflections of countrywide applications and their rationale**
Vahip S., Yazici O., Akdeniz F., Gonul A., Karadag F., Kocadere M., Kora K., Oral E., Ozerdem A., Ozpoyraz N., et al.
JOURNAL OF AFFECTIVE DISORDERS, vol.78, 2004 (SCI-Expanded)

XCVIII. **Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia**
Ucok A., Polat A., Genc A., Cakir S., Turan N.
JOURNAL OF PSYCHIATRIC RESEARCH, vol.38, no.2, pp.163-168, 2004 (SCI-Expanded)

XCIX. **Attitudes of psychiatrists toward patients with schizophrenia**
Ucok A., Polat A., Sartorius N., Erkoc S., Atakli C.
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.58, no.1, pp.89-91, 2004 (SCI-Expanded)

C. **Treatment guidelines for bipolar disorders of Psychiatric Association of Turkey**
Vahip S., Yazici O., Akdeniz F., Gonul A., Karadag F., Kocadere M., Kora K., Oral E., Ozerdem A., Ozpovraz N., et al.
ACTA PSYCHIATRICA SCANDINAVICA, vol.110, pp.40, 2004 (SCI-Expanded)

CI. **Quetiapine treatment in a patients with Tourette's syndrome, obsessive-compulsive disorder and drug-induced mania**
Matur Z., Ucok A.
ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES, vol.40, no.2, pp.150-152, 2003 (SSCI)

CII. **Unipolar mania: a distinct disorder?**
Yazici O., Kora K., Ucok A., Saylan M., Ozdemir O., Kiziltan E., Ozpulat T.
JOURNAL OF AFFECTIVE DISORDERS, vol.71, pp.97-103, 2002 (SCI-Expanded)

CIII. **Relation of family history of schizophrenia with clinical variables in patients with schizophrenia**
Ucok A., Kultur S., Alptekin K., Erkoc S., Gogus A., Mete L., Yazici M.
SCHIZOPHRENIA RESEARCH, vol.53, no.3, pp.81, 2002 (SCI-Expanded)

CIV. **Predictors of relapse following response from a first episode of schizophrenia**
Ucok A., Polat A., Saylan M., Turan N.
SCHIZOPHRENIA RESEARCH, vol.53, no.3, pp.54, 2002 (SCI-Expanded)

CV. **A multi-center 1-year follow-up study of patients with schizophrenia in Turkey: Relapse and its predictors**

Ucok A., Kultur S., Alptekin K., Erkoc S., Gogus A., Mete L., Yazici M.
SCHIZOPHRENIA RESEARCH, vol.53, no.3, pp.251, 2002 (SCI-Expanded)

CVI. **Disability in schizophrenia: A multicenter study of 1-year follow-up of patients with schizophrenia in Turkey**
ALPTEKİN K., Erkoc S., GÖĞÜŞ A. K., Kultur S., Mete L., ÜÇOK V. A., Yazc K.
SCHIZOPHRENIA RESEARCH, vol.53, no.3, pp.261, 2002 (SCI-Expanded)

CVII. **Co-morbid substance abuse and smoking in Turkish patients with schizophrenia**
ALPTEKİN K., Erkoc S., GÖĞÜŞ A. K., Kultur S., Mete L., ÜÇOK V. A., Yazc K.
SCHIZOPHRENIA RESEARCH, vol.53, no.3, pp.224, 2002 (SCI-Expanded)

CVIII. **Predictors of lithium prophylaxis in bipolar patients**
Yazici O., Kora K., Ucok A., Tunali D., Turan N.
JOURNAL OF AFFECTIVE DISORDERS, vol.55, pp.133-142, 1999 (SCI-Expanded)

CIX. **Comorbidity of personality disorders with bipolar mood disorders**
Ucok A., KARAVELI D., KUNDAKCI T., YAZICI O.
COMPREHENSIVE PSYCHIATRY, vol.39, no.2, pp.72-74, 1998 (SCI-Expanded)

CX. **Seclusion in closed psychiatric wards in Turkey**
Ucok V. A., KORA K., BOSTANCI F., ER F.
EUROPEAN JOURNAL OF PSYCHIATRY, vol.10, no.3, pp.149-154, 1996 (SSCI)

CXI. **Maintenance ECT in a patient with catatonic schizophrenia and tardive dyskinesia**
Ucok A., Ucok G.
CONVULSIVE THERAPY, vol.12, no.2, pp.108-112, 1996 (SCI-Expanded)

CXII. **NORADRENERGIC AND SEROTONINERGIC DEPRESSION**
YAZICI O., ARICIOGLU F., GURVIT G., UCOK A., TASTABAN Y., CANBERK O., OZGUROGLU M., DURAT T., SAHIN D.
JOURNAL OF AFFECTIVE DISORDERS, vol.27, no.2, pp.123-129, 1993 (SCI-Expanded)

## Articles Published in Other Journals

I. **Face and emotion recognition in individuals diagnosed with schizophrenia, ultra-high risk for psychosis, unaffected siblings, and healthy controls in a sample from Turkey**
Sağdıç M., Izgi B., Yapici Eser H., Ercis M., Üçok A., Kuşçu K.
Schizophrenia Research: Cognition, vol.36, 2024 (ESCI)

II. **Antistigma Efforts in Turkey The Turkish Program Against Stigmatization and Discrimination Because of Schizophrenia as a Part of the World Psychiatric Association Global Program**
Soygur H., ÜÇOK V. A., Akbiyik D. I.
INTERNATIONAL JOURNAL OF MENTAL HEALTH, vol.36, no.3, pp.58-65, 2007 (ESCI)

III. **The Efficacy of Psychoeducational Group Therapy in Inpatients**
ÇETİNKAYA DUMAN Z., Kocaman N., ÜÇOK V. A., Er F., Kanik T., Doganer M.
DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES, vol.19, no.2, pp.64-71, 2006 (ESCI)

## Books & Book Chapters

I. **İlk episod şizofreni ; yaklaşım ve tedavi ilkeleri**
ÜÇOK V. A.
in: Temel ve Klinik Psikiyatri, K Oğuz Karamustafalıoğlu, Editor, Güneş Tıp Kitapevi Yayınları, Ankara, pp.229-234, 2018

II. **Şizofreni**
ÜÇOK V. A., ALNAK A.
in: Maudsley Psikiyatride Reçeteleme Rehberi, Üçok A, Editor, Ema Tıp Kitabevi, İstanbul, pp.44-201, 2017

III. **Mikroplar ve psikiyatrik bozukluklar**

ÜÇOK V. A.
in: Enfeksiyon patogenezi ve bağışıklık, Badur S., Abacıoğlu H., Öngen B., Editor, Akademi Yayınevi, İstanbul, pp.1341-1345, 2015

IV. **Psikanalitik Kurama Giriş**
AKVARDAR Y., TÜKEL M. R., ÜÇOK V. A., YÜCEL B.
Bağlam, 2000

## Refereed Congress / Symposium Publications in Proceedings

I. **Pregnancy and postpartum period associated severe mental disorders in a hospital-based cohort**
Büyüktopcu E., Gürşahbaz O. C., Ergün S., Keskin M., Köroğlu S. B., Ozan E., Direk Tecirli N., Üçok V. A.
35th ECNP Congress, Vienna, Austria, 15 - 18 October 2022, vol.1,2, pp.357-358

II. Doğan E. E., Mutlu Ü., Hacişahinoğulları H., Gürşahbaz O. C., Üçok V. A., Soyluk Selçukbiricik Ö., Gül N., Kubat Üzüm A., Beşışık S., Karşıdağ K.
Endokurs 5, Antalya, Turkey, 10 - 14 November 2021, pp.148

III. **Negatif Belirtiler Özdeğerlendirme Ölçeğinin Türkçe Geçerlik ve Güvenilirlik Çalışması**
Polat I., İnce Guliyev E., Elmas S., Abdulhamid S., Aydemir Ö., Üçok V. A.
55. Ulusal Psikiyatri Kongresi, İstanbul, Turkey, 23 - 27 October 2019, vol.30, pp.44

IV. **RELATIONSHIP BETWEEN FORMAL THOUGHT DISORDER, AND FUNCTIONING IN INDIVIDUALS WITH ULTRA HIGH RISK FOR PSYCHOSIS**
Ucok A., Senay O., Karakas B.
Congress of the Schizophrenia-International-Research-Society (SRIS), Florida, United States Of America, 10 - 14 April 2019, vol.45

V. **Neurocognition for the classification of first episode schizophrenia, unaffected family members and healthy controls: A machine learning study**
Ince E., Kalmady S. V., Greiner R., Dursun S., Ucok A.
31st Congress of the European-College-of-Neuropsychopharmacology (ECNP), Barcelona, Spain, 6 - 09 October 2018

VI. **ŞİZOFRENİ HASTALARI VE KARDEŞLERİNDE KİNÜRENİN YOLAĞI METABOLİTLERİ, VİTAMİN D VE İNFLAMASYON BELİRTEÇLERİNİN KOGNİSYON VE KLİNİK BELİRTİLERLE İLİŞKİSİ**
Noyan H., TÜZÜN E., Erdağ E., HAKAN M. T., KÜÇÜKHÜSEYİN Ö., YAYLIM İ., ÜÇOK V. A.
II. Türkiye in vitro Diyagnostik(IVD)Sempozyumu, İzmir, Turkey, 10 - 22 May 2017, pp.1

VII. **LOWER PREPULSE INHIBITION IN CLINICAL HIGH-RISK GROUP BUT NOT IN FAMILIAL RISK GROUP FOR PSYCHOSIS COMPARED TO HEALTHY CONTROLS**
Ucok A., Togay B., Cikrikcili U., Bayraktaroglu Z.
16th International Congress on Schizophrenia Research (ICOSR), California, United States Of America, 24 - 28 March 2017, vol.43

VIII. **Psikoz için yüksek risk grubundaki bireylerde dinlenim durumu fonksiyonel manyetik rezonans görüntüleme bulgularının sağlıklı kontroller ile karşılaştırılması**
BÜLBÜL Ö., KURT E., Ulaşoğlu Yıldız Ç., Kıçik A., DEMİRALP T., Noyan H., ÇAĞLAR N., ERGÜL C., KAYA H., YOKUŞOĞLU Ç., et al.
52. Ulusal Psikiyatri Kongresi, Antalya, Turkey, 16 - 20 November 2016, pp.11-12

IX. **Kısa Negatif Belirti Ölçeğinin Türkçe Geçerlilik ve Güvenilirlik Çalışması**
Polat I., Ergül C., Aydemir Ö., Üçok V. A., Gönül A. S.
51. Ulusal Psikiyatri Kongresi, Antalya, Turkey, 25 - 29 November 2015, pp.77

X. **Şizofrenili Hastalarda Anhedoninin Alt Bileşenleri ile İlgili Değişkenler**
Ergül C., Polat I., Aydemir Ö., Gönül A. S., Üçok V. A.
51. Ulusal Psikiyatri Kongresi, Antalya, Turkey, 25 - 29 November 2015, pp.129

XI. **Şizofrenili Hastalarda Negatif Belirtiler ile İlgili Değişkenler**
Ergül C., Polat Nazli I., Aydemir Ö., Gönül A. S., Üçok V. A.

51. Ulusal Psikiyatri Kongresi, Antalya, Turkey, 25 - 29 November 2015, pp.129

XII. **HISTORY OF CHILDHOOD PHYSICAL TRAUMA HAS A NEGATIVE IMPACT ON COGNITIVE FUNCTIONING IN INDIVIDUALS AT ULTRA HIGH RISK FOR PSYCHOSIS**
Ucok A.
15th International Congress on Schizophrenia Research (ICOSR), Colorado, United States Of America, 28 March - 01 April 2015, vol.41

XIII. **evalualtion ofcognition in the first degree relatives of patients with schizophreia: Association between negative schizotypal personality traits and cognitive dysfunctions**
Noyan H., ÜÇOK V. A.
1st Joint Turkish-German Symposium on human neuroscience, Berlin, Germany, 5 - 07 June 2014, vol.1, no.1, pp.30-31

XIV. **P300 AMPLITUDE REDUCTION IN SUBJECTS AT ULTRA HIGH-RISK FOR PSYCHOSIS**
Keskin-Ergen H. Y., Ucok A., Gode E., Devrim-Ucok M.
2nd Conference of the Schizophrenia-International-Research-Society (SIRS), Florence, Italy, 10 - 14 April 2010, vol.117, pp.361-362

XV. **CHILDHOOD TRAUMA MAY BE RELATED TO TRANSITION TO PSYCHOSIS IN ULTRA HIGH RISK INDIVIDUALS**
Sahin S., ÜÇOK V. A., Code E., Yuksel C.
2nd Conference of the Schizophrenia-International-Research-Society (SIRS), Florence, Italy, 10 - 14 April 2010, vol.117, pp.204

XVI. **GO AND NOGO P300 ARE NOT IMPAIRED IN SUBJECTS AT ULTRA HIGH-RISK FOR PSYCHOSIS**
Devrim-Ucok M., Keskin-Ergen H. Y., Yuksel C., Sahin S., Ucok A.
2nd Conference of the Schizophrenia-International-Research-Society (SIRS), Florence, Italy, 10 - 14 April 2010, vol.117, pp.245

XVII. **A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia**
Schreiner A., Korcsog P., Niehaus D. J., Aadamsoo K., Ucok A., Franco M., Theodoropoulou P., Salinas R., Bergmans P., Hoeben D.
27th Collegium Internationale Neuro-Psychopharmacologicum Congress, Hong Kong, PEOPLES R CHINA, 6 - 10 June 2010, vol.13, pp.239

XVIII. **P3B AMPLITUDE REDUCTION IS NOT PROGRESSIVE OVER THE COURSE OF SCHIZOPHRENIA AFTER THE ONSET OF ILLNESS**
Ucok A., Ergen Y. K., Ucok M. D.
12th International Congress on Schizophrenia Research, California, United States Of America, 28 March - 01 April 2009, vol.35, pp.44

XIX. **Single-voxel quantitative proton MR spectroscopy in corpus callosum of patients with schizophrenia: Suggests callosal disconnection**
Ucok A., Aydin K., Cakir S., Ciftci K.
10th International Congress on Schizophrenia Research, Savannakhet, Laos, 2 - 06 April 2005, vol.33, pp.358

XX. **Association of cognitive functions and interpersonal problem solving capacity with serotonin (102T/C) receptor polymorphism in schizophrenia**
Ucok A., Alpsan H., Cakir S., Ozdemir F., Direskeneli G.
13th Biennial Winter Workshop on Schizophrenia Research, Davos, Switzerland, 4 - 10 February 2006, vol.81, pp.197

XXI. **Nogo P3 reduction reflects impairment in response inhibition processes in recent-onset schizophrenia**
Ertekin E., Keskin-Ergen H., Ucok M., Ucok A.
13th Biennial Winter Workshop on Schizophrenia Research, Davos, Switzerland, 4 - 10 February 2006, vol.81, pp.110-111

XXII. **Evaluation of sexual functions of schizophrenic patients under antipsychotics: Multicentered, uninterventional, cross-sectional, epidemiologic study**

Aker T., ÜÇOK V. A., Incesu C., Erkoc S.
18th ECNP Congress 2005, Amsterdam, Netherlands, 22 - 26 October 2005, vol.15

XXIII. **P3B and novelty P3A in first-episode and chronic schizophrenia**
Ucok M., Ucok A., Keskin Y., Cakir S., Discigil A., Polat A.
12th Biennial Winter Workshop on Schizophrenia, DAVOS, Switzerland, 7 - 13 February 2004, vol.67, pp.134

XXIV. **Cognitive predictors of skill acquisition on interpersonal problem solving in patients with schizophrenia**
Ucok A., Cetinkaya Z., Cakir S., Discigil A., Kandemir P., Atli H.
12th Biennial Winter Workshop on Schizophrenia, DAVOS, Switzerland, 7 - 13 February 2004, vol.67, pp.261

XXV. **The distribution of suicidal behavior and risk factors in patients diagnosed with schizophrenia in a one-year multicenter follow-up study**
GÖĞÜŞ A. K., ALPTEKİN K., Erkoc S., Kultur S., Mete L., ÜÇOK V. A., Yazici M.
9th International Congress on Schizophrenia Research, COLORADO SPINGS, COLORADO, 29 March - 02 April 2003, vol.60, pp.16

## Supported Projects

ÜÇOK V. A., Project Supported by Higher Education Institutions, Schneider symptoms? effect on relapse, remission, symptom severity and life quality in first episode schizophrenia patients during the follow-up period., 2013 - 2016
ÜÇOK V. A., Project Supported by Higher Education Institutions, Delayed initiation of clozapine may be related with poor response in treatment- resistant schizophrenia, 2015 - 2015
ÜÇOK V. A., Project Supported by Higher Education Institutions, Effects of different negative symptom subgroups on functionality in patients with first episode schizophrenia, 2014 - 2014
ÜÇOK V. A., Project Supported by Higher Education Institutions, REMISSION IN LONG TERM FOLLOW UP AFTER FIRST EPISODE OF SCHIZOPHRENIA, 2013 - 2013
ÜÇOK V. A., Project Supported by Higher Education Institutions, Şizofreni hastalarında stigma ve ayırımcılık beklentisinin belirti şiddeti, işlevsellik ve yaşam kalitesiyle ilişkisi, 2011 - 2013
ÜÇOK V. A., Project Supported by Higher Education Institutions, Şizofreni Hastalarının Birinci Dereceden Akrabalarında Şizotipinin Alt Tiplerine Özgü Kognitif Bozuklukların İncelenmesi, 2010 - 2011
ÜÇOK V. A., Project Supported by Higher Education Institutions, Şizofrenide DRD2 C957T SNP Polimorfizmi ve COMT Val158Met Polimorfizminin Yürütücü fonksiyonlar üzerine etkileşimi, 2009 - 2011
ÜÇOK V. A., Project Supported by Higher Education Institutions, Relationship between anticipated discrimination and severity of symptoms and functionality in schizophrenia, 2010 - 2010
ÜÇOK V. A., Project Supported by Higher Education Institutions, P50 gating at acute and post-acute phases of schizophrenia, 2008 - 2008

## Metrics

Publication: 144
Citation (WoS): 3992
Citation (Scopus): 1969
H-Index (WoS): 34
H-Index (Scopus): 25

## Non Academic Experience

UCLA Psikiyatri departmanı, USA